Who Are We?
Confidence and Quality
We are a global biotechnology company dedicated to the research, development and marketing of medical and cosmeceuticals products. We specialize in orphan drugs for catastrophic, uncommon illnesses and highly specialized pathologies, which are potentially deadly. We work directly with the best laboratories in the world and under the main regulatory bodies WHO, USFDA, MHRA, EMEA, AEMSP, PAHO, INVIMA and DIGEMID.

International Scope
As an organization and as allies in health, we work with different partners and institutions around the world to develop new products, innovative projects and marketing channels
Research and Development in the Health Sector
We work to contribute continuously in the modernization of technologies in the Health and Cosmetics sector to improve the standard of living of all people, offering a range of products with high international quality standards. I read well and feel better. This includes working under the GDP and GMP standards.
Good Manufacturing Practice
Our processes include, certification in Good Manufacturing Practices (GMP) that guarantee the use of quality raw materials, appropriate facilities for manufacturing and adequate and sufficient tests to demonstrate the quality of the product Good Manufacturing Practices.
International Safety Standards and regulations
We verify that all medicines that are marketed, including cosmeceuticals products, comply with international safety standards and regulations, focus on effectiveness and quality before placing them in the hands of consumers.
Specialized Communication Channels
We have a direct communication laboratory – provider – client, in order to offer timely solutions and specialized advice when required, achieving to improve our communication channels and customer service.
Expansion
INTERNATIONAL SCOPE


NEWS IBEROPHARMA
NEWS FROM THE SCIENTIFIC AND MEDICAL WORLD
Blog Iberopharma

Avances Médicos en el Tiramiento contra el Cáncer OMS
Según la OMS la terapia de células T con CAR, que es un tipo de inmunoterapia celular adoptiva, se realiza de manera personalizada para cada…

INFORMACIÓN RELACIONADA CON EL TRATAMIENTO CON OLARATUMAB (▼LARTRUVO®)
El titular del medicamento Lartruvo ha comunicado los resultados del estudio post-autorización requerido como condición de su autorización. Los resultados no confirman el beneficio clínico…

Inmunoterapia de células T con CAR: el Avance del año
A principios de cada año, la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica, ASCO por sus siglas en inglés) publica su informe…
